These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
99 related articles for article (PubMed ID: 7638815)
1. Salmeterol inhaler using a non-chlorinated propellant, HFA134a: systemic pharmacodynamic activity in healthy volunteers. Kirby SM; Smith J; Ventresca GP Thorax; 1995 Jun; 50(6):679-81. PubMed ID: 7638815 [TBL] [Abstract][Full Text] [Related]
2. Comparison of the systemic pharmacodynamic effects and pharmacokinetics of salmeterol delivered by CFC propellant and non-CFC propellant metered dose inhalers in healthy subjects. Kempsford R; Handel M; Mehta R; De Silva M; Daley-Yates P Respir Med; 2005 Apr; 99 Suppl A():S11-9. PubMed ID: 15777604 [TBL] [Abstract][Full Text] [Related]
5. Salmeterol and fluticasone propionate given as a combination. Lack of systemic pharmacodynamic and pharmacokinetic interactions. Kirby S; Falcoz C; Daniel MJ; Milleri S; Squassante L; Ziviani L; Ventresca GP Eur J Clin Pharmacol; 2001; 56(11):781-91. PubMed ID: 11294367 [TBL] [Abstract][Full Text] [Related]
6. Therapeutic equivalence of a novel HFA134a-containing metered-dose inhaler and the conventional CFC inhaler (Berodual) for the delivery of a fixed combination of fenoterol/ipratropium bromide. A randomized double-blind placebo-controlled crossover study in patients with asthma. Maesen FP; Greefhorst LP; Smeets JJ; Wald FD; Cornelissen PJ Respiration; 1997; 64(4):273-80. PubMed ID: 9257362 [TBL] [Abstract][Full Text] [Related]
7. Effects of fluticasone propionate and salmeterol hydrofluoroalkane inhalation aerosol on asthma-related quality of life. Edin HM; Andersen LB; Schoaf L; Scott-Wilson CA; Ho SY; Ortega HG Ann Allergy Asthma Immunol; 2009 Apr; 102(4):323-7. PubMed ID: 19441604 [TBL] [Abstract][Full Text] [Related]
8. Acute safety of the CFC-free propellant HFA-134a from a pressurized metered dose inhaler. Donnell D; Harrison LI; Ward S; Klinger NM; Ekholm BP; Cooper KM; Porietis I; McEwen J Eur J Clin Pharmacol; 1995; 48(6):473-7. PubMed ID: 8582466 [TBL] [Abstract][Full Text] [Related]
9. Time course and relative dose potency of systemic effects from salmeterol and salbutamol in healthy subjects. Bennett JA; Tattersfield AE Thorax; 1997 May; 52(5):458-64. PubMed ID: 9176539 [TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and pharmacodynamics of fluticasone propionate and salmeterol delivered as a combination dry powder from a capsule-based inhaler and a multidose inhaler in asthma and COPD patients. Daley-Yates PT; Mehta R; Chan RH; Despa SX; Louey MD J Aerosol Med Pulm Drug Deliv; 2014 Aug; 27(4):279-89. PubMed ID: 24074143 [TBL] [Abstract][Full Text] [Related]
11. Efficacy and tolerability of fluticasone propionate/salmeterol administered twice daily via hydrofluoroalkane 134a metered-dose inhaler in adolescent and adult patients with persistent asthma: a randomized, double-blind, placebo-controlled, 12-week study. Nathan RA; Rooklin A; Schoaf L; Scott C; Ellsworth A; House K; Dorinsky P Clin Ther; 2006 Jan; 28(1):73-85. PubMed ID: 16490581 [TBL] [Abstract][Full Text] [Related]
12. Does tachyphylaxis occur to the non-pulmonary effects of salmeterol? Maconochie JG; Minton NA; Chilton JE; Keene ON Br J Clin Pharmacol; 1994 Feb; 37(2):199-204. PubMed ID: 7910472 [TBL] [Abstract][Full Text] [Related]
13. A comparison of the efficacy and tolerability of single doses of HFA 134a albuterol and CFC albuterol in mild-to-moderate asthmatic patients. Langley SJ; Sykes AP; Batty EP; Masterson CM; Woodcock A Ann Allergy Asthma Immunol; 2002 May; 88(5):488-93. PubMed ID: 12027070 [TBL] [Abstract][Full Text] [Related]
14. The contribution of the swallowed fraction of an inhaled dose of salmeterol to it systemic effects. Bennett JA; Harrison TW; Tattersfield AE Eur Respir J; 1999 Feb; 13(2):445-8. PubMed ID: 10065696 [TBL] [Abstract][Full Text] [Related]
15. Salmeterol: a novel, long-acting beta 2-agonist. Meyer JM; Wenzel CL; Kradjan WA Ann Pharmacother; 1993 Dec; 27(12):1478-87. PubMed ID: 7905757 [TBL] [Abstract][Full Text] [Related]
16. Dose-response study with high-dose inhaled salmeterol in healthy subjects. Maconochie JG; Forster JK Br J Clin Pharmacol; 1992 Mar; 33(3):342-5. PubMed ID: 1349491 [TBL] [Abstract][Full Text] [Related]
17. Salmeterol HFA is as effective as salmeterol CFC in children and adults with persistent asthma. Chopra N; Williams M; Rimmer M; Kahl L; Jenkins M; Respir Med; 2005 Apr; 99 Suppl A():S1-S10. PubMed ID: 15777603 [TBL] [Abstract][Full Text] [Related]
18. Interaction and dose equivalence of salbutamol and salmeterol in patients with asthma. Smyth ET; Pavord ID; Wong CS; Wisniewski AF; Williams J; Tattersfield AE BMJ; 1993 Feb; 306(6877):543-5. PubMed ID: 8096416 [TBL] [Abstract][Full Text] [Related]
19. Development and performance of a new hydrofluoroalkane (HFA 134a)-based metered dose inhaler (MDI) of salmeterol. Peyron ID; Britto IL; Benissan LB; Tardieu BZ Respir Med; 2005 Apr; 99 Suppl A():S20-30. PubMed ID: 15777605 [TBL] [Abstract][Full Text] [Related]